BioCentury | May 9, 2016
Clinical News

CMX-2043: Phase II data

...Canadian Phase II CARIN trial in 361 patients undergoing cardiac catheterization procedures showed that IV CMX-2043...
...later, 2.4 mg/kg IV CMX-2043 given once prior to catheterization followed by 2.4 mg/kg IV CMX-2043...
...at the American College of Cardiology meeting in Chicago. Ischemix Inc. , Maynard, Mass. Product: CMX-2043...
BioCentury | Oct 12, 2015
Clinical News

CMX-2043: Completed Phase IIa enrollment

...doses of 2.4 mg/kg CMX-2043 given 24 hours apart. Ischemix Inc. , Maynard, Mass. Product: CMX-2043...
BioCentury | Jul 14, 2014
Clinical News

CMX-2043: Phase IIa started

...placebo-controlled Phase IIa CARIN trial to evaluate single doses of 2.4 and 3.6 mg/kg IV CMX-2043...
...time it plans to start discussions with potential partners. Ischemix Inc ., Maynard, Mass. Product: CMX-2043...
BioCentury | Jul 4, 2011
Clinical News

CMX-2043: Phase IIa data

...data from a double-blind, placebo-controlled Phase IIa trial in patients undergoing PCI showed that IV CMX-2043...
...tested, which Ischemix said met the primary endpoint of safety. Ischemix , Maynard, Mass. Product: CMX-2043...
BioCentury | Mar 15, 2010
Clinical News

CMX-2043: Phase IIa started

...0.8, 1.6, and 2.4 mg/kg intravenous CMX-2043 in 220 patients. Ischemix , Maynard, Mass. Product: CMX-2043...
Items per page:
1 - 5 of 5